Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel With or Without Prednisone in mCRPC (CABACARE)
NCT03356912Phase 2Unknown
- Sponsor
- Consorzio Oncotech
- Start
- Nov 2017
- Primary completion
- May 2021
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cabazitaxel ginsenoside liposome injection in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Consorzio Oncotech. Primary endpoint: Radiographic Progression-Free Survival. Status: unknown.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03356912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03356912.